ProductsBack/Dopamine Receptor D1 antibody [C2C3], C-term

Dopamine Receptor D1 antibody [C2C3], C-term

Name: Dopamine Receptor D1 antibody [C2C3], C-term
SKU: GTX100354_G10
Availability: BackOrder

GTX100354

ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin

Product group Antibodies

TargetDRD1

Overview

Supplier
GeneTex
Product Name
Dopamine Receptor D1 antibody [C2C3], C-term
Delivery Days Customer
9
Application Supplier Note
WB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. IHC-Fr: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
Applications
ImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin
Certification
Research Use Only
Clonality
Polyclonal
Concentration
2 mg/ml
Conjugate
Unconjugated
Gene ID1812
Target name
DRD1
Target description
dopamine receptor D1
Target synonyms
D1R, DADR, DRD1A, D(1A) dopamine receptor, dopamine D1 receptor
Host
Rabbit
Isotype
IgG
Protein IDP21728
Protein Name
D(1A) dopamine receptor
Scientific Description
This gene encodes the D1 subtype of the dopamine receptor. The D1 subtype is the most abundant dopamine receptor in the central nervous system. This G-protein coupled receptor stimulates adenylyl cyclase and activates cyclic AMP-dependent protein kinases. D1 receptors regulate neuronal growth and development, mediate some behavioral responses, and modulate dopamine receptor D2-mediated events. Alternate transcription initiation sites result in two transcript variants of this gene. [provided by RefSeq]
Storage Instruction
-20°C or -80°C,2°C to 8°C
UNSPSC
12352203

Li H, Sun F, Bai S, et al. The DR1‑CSE/H(2)S system inhibits renal fibrosis by downregulating the ERK1/2 signaling pathway in diabetic mice. Int J Mol Med. 2022,49(1):pii: 7. doi: 10.3892/ijmm.2021.5062.
Read this paper
Tapia E, García-Arroyo F, Silverio O, et al. Mycophenolate mofetil and curcumin provide comparable therapeutic benefit in experimental chronic kidney disease: role of Nrf2-Keap1 and renal dopamine pathways. Free Radic Res. 2016,50(7):781-92. doi: 10.1080/10715762.2016.1174776
Read this paper